118 research outputs found
Efectos de la inhibición no selectiva de los receptores de endotelina (ETa y ETb) en la formación de tejido neointimal tras angioplastia coronaria en un modelo porcino
Tesis de la Universidad Complutense de Madrid, Facultad de Medicina, leída el 04-06-2003Fac. de MedicinaTRUEpu
Ivabradine-Stimulated Microvesicle Release Induces Cardiac Protection against Acute Myocardial Infarction.
Ivabradine can reduce heart rate through inhibition of the current I(f ) by still unexplored
mechanisms. In a porcine model of ischemia reperfusion (IR), we found that treatment with 0.3 mg/kg
Ivabradine increased plasma release of microvesicles (MVs) over Placebo, as detected by flow
cytometry of plasma isolated from pigs 7 days after IR, in which a tenfold increase of Extracellular
Matrix Metalloproteinase Inducer (EMMPRIN) containing (both high and low-glycosylated) MVs,
was detected in response to Ivabradine. The source of MVs was investigated, finding a 37% decrease
of CD31+ endothelial cell derived MVs, while CD41+ platelet MVs remained unchanged. By contrast,
Ivabradine induced the release of HCN4+ (mostly cardiac) MVs. While no differences respect to
EMMPRIN as a cargo component were found in endothelial and platelet derived MVs, Ivabradine
induced a significant release of EMMPRIN+/HCN4+ MVs by day 7 after IR. To test the role of
EMMPRIN+ cardiacMVs (EMCMV), H9c2 cellmonolayers were incubated for 24 h with 107 EMCMVs,
reducing apoptosis, and increasing 2 times cell proliferation and 1.5 times cell migration. The in vivo
contribution of Ivabradine-induced plasma MVs was also tested, in which 108 MVs isolated from
the plasma of pigs treated with Ivabradine or Placebo 7 days after IR, were injected in pigs under IR,
finding a significant cardiac protection by increasing left ventricle ejection fraction and a significant
reduction of the necrotic area. In conclusion ivabradine induces cardiac protection by increasing at
least the release of EMMPRIN containing cardiac microvesicles.post-print1810 K
Senescent mesenchymal stem/stromal cells in pre-metastatic bone marrow of untreated advanced breast cancer patients
Breast cancer is the predominant form of carcinoma among women worldwide, with 70% of advanced patients developing bone metastases, with a high mortality rate. In this sense, the bone marrow (BM) mesenchymal stem/stromal cells (MSCs) are critical for BM/bone homeostasis, and failures in their functionality, transform the BM into a pre-metastatic niche (PMN). We previously found that BM-MSCs from advanced breast cancer patients (BCPs, infiltrative ductal carcinoma, stage III-B) have an abnormal profile. This work aims to study some of the metabolic and molecular mechanisms underlying MSCs shift from a normal to an abnormal profile in this group of patients. A comparative analysis was undertaken, which included self-renewal capacity, morphology, proliferation capacity, cell cycle, reactive oxygen species (ROS) levels, and senescence-associated β‑galactosidase (SA‑β‑gal) staining of BM-derived MSCs isolated from 14 BCPs and 9 healthy volunteers (HVs). Additionally, the expression and activity of the telomerase subunit TERT, as well as telomere length, were measured. Expression levels of pluripotency, osteogenic, and osteoclastogenic genes (OCT-4, SOX-2, M-CAM, RUNX-2, BMP-2, CCL-2, M-CSF, and IL-6) were also determined. The results showed that MSCs from BCPs had reduced ,self-renewal and proliferation capacity. These cells also exhibited inhibited cell cycle progression and phenotypic changes, such as an enlarged and flattened appearance. Additionally, there was an increase in ROS and senescence levels and a decrease in the functional capacity of TERT to preserve telomere length. We also found an increase in pro-inflammatory/pro-osteoclastogenic gene expression and a decrease in pluripotency gene expression. We conclude that these changes could be responsible for the abnormal functional profile that MSCs show in this group of patients.Fil: Borzone, Francisco Raúl. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Giorello, Maria Belen. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Martinez, Leandro Marcelo. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina. Weill Cornell Medical College; Estados UnidosFil: Sanmartin, María Cecilia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Medicina Traslacional, Trasplante y Bioingeniería. Fundación Favaloro. Instituto de Medicina Traslacional, Trasplante y Bioingeniería; ArgentinaFil: Feldman, Leonardo. Universidad Nacional del Centro de la Pcia.de Bs.as.. Facultad de Ciencias de la Salud.; ArgentinaFil: Dimase, Federico. Ministerio de Defensa. Ejército Argentino. Hospital Militar Central Cirujano Mayor "Dr. Cosme Argerich"; ArgentinaFil: Batagelj, Emilio. Ministerio de Defensa. Ejército Argentino. Hospital Militar Central Cirujano Mayor "Dr. Cosme Argerich"; ArgentinaFil: Yannarelli, Gustavo Gabriel. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Medicina Traslacional, Trasplante y Bioingeniería. Fundación Favaloro. Instituto de Medicina Traslacional, Trasplante y Bioingeniería; ArgentinaFil: Chasseing, Norma Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentin
Incidencia de las intoxicaciones: un caso en hospital de Ecuador / Incidence of intoxication: a case in an Ecuadorian hospital
Las intoxicaciones son un problema de salud pública y una de las principales causas de ingresos en las salas de emergencias a nivel nacional e internacional. Se realizó una investigación exploratoria, descriptiva, transversal y de observación dirigida, para determinar la incidencia de las intoxicaciones en pacientes del Hospital General Teófilo Dávila de la Provincia de El Oro, Ecuador, año 2012, por edad, sexo, procedencia y tóxicos más frecuentes en este medio. La mayor incidencia ocurrió el mes de febrero (16,35%), la muestra de 104 intoxicados, predominó el sexo masculino (66,35%), procedencia urbana (88,46%) y el grupo etario de 20-49 años (60,58%). Las circunstancias, accidental (78,85%), intencional (16,35%) y laboral (4,81%). El mecanismo más relevante fue la ingesta (84,62%), los tipos de agente son, los alimentos/bebidas (29,81%) y las sustancias de abuso (25%). Abstract Intoxication is a public health problem and one of the main causes of admission in emergency rooms nationwide and internationally. An exploratory, descriptive, and cross sectional research of a directed observation was conducted to determine the incidence of intoxication in patients of General Teófilo Dávila Hospital in El Oro Province, Ecuador, in 2012; patients were classified by age, sex, origin, and the most frequent toxicant in this area. The highest incidence was February (16.35%), in the sample of 104 intoxicated males predominated (66.35%), urban origin (88.46%) and the age group of 20-49 years (60.58%). The circumstances were: accidental (78.85%), intentional (16, 35 %) and employment (4.81%). The most important mechanism is the intake (84.62 %), the agent types are food / beverages (29.81 %) and substance abuse (25%)
High Levels of Diversity Uncovered in a Widespread Nominal Taxon: Continental Phylogeography of the Neotropical Tree Frog
Species distributed across vast continental areas and across major biomes provide unique model systems for studies of biotic diversification, yet also constitute daunting financial, logistic and political challenges for data collection across such regions. The tree frog Dendropsophus minutus (Anura: Hylidae) is a nominal species, continentally distributed in South America, that may represent a complex of multiple species, each with a more limited distribution. To understand the spatial pattern of molecular diversity throughout the range of this species complex, we obtained DNA sequence data from two mitochondrial genes, cytochrome oxidase I (COI) and the 16S rhibosomal gene (16S) for 407 samples of D. minutus and closely related species distributed across eleven countries, effectively comprising the entire range of the group. We performed phylogenetic and spatially explicit phylogeographic analyses to assess the genetic structure of lineages and infer ancestral areas. We found 43 statistically supported, deep mitochondrial lineages, several of which may represent currently unrecognized distinct species. One major clade, containing 25 divergent lineages, includes samples from the type locality of D. minutus. We defined that clade as the D. minutus complex. The remaining lineages together with the D. minutus complex constitute the D. minutus species group. Historical analyses support an Amazonian origin for the D. minutus species group with a subsequent dispersal to eastern Brazil where the D. minutus complex originated. According to our dataset, a total of eight mtDNA lineages have ranges >100,000 km2. One of them occupies an area of almost one million km2 encompassing multiple biomes. Our results, at a spatial scale and resolution unprecedented for a Neotropical vertebrate, confirm that widespread amphibian species occur in lowland South America, yet at the same time a large proportion of cryptic diversity still remains to be discovered
LHCb upgrade software and computing : technical design report
This document reports the Research and Development activities that are carried out in the software and computing domains in view of the upgrade of the LHCb experiment. The implementation of a full software trigger implies major changes in the core software framework, in the event data model, and in the reconstruction algorithms. The increase of the data volumes for both real and simulated datasets requires a corresponding scaling of the distributed computing infrastructure. An implementation plan in both domains is presented, together with a risk assessment analysis
Physics case for an LHCb Upgrade II - Opportunities in flavour physics, and beyond, in the HL-LHC era
The LHCb Upgrade II will fully exploit the flavour-physics opportunities of the HL-LHC, and study additional physics topics that take advantage of the forward acceptance of the LHCb spectrometer. The LHCb Upgrade I will begin operation in 2020. Consolidation will occur, and modest enhancements of the Upgrade I detector will be installed, in Long Shutdown 3 of the LHC (2025) and these are discussed here. The main Upgrade II detector will be installed in long shutdown 4 of the LHC (2030) and will build on the strengths of the current LHCb experiment and the Upgrade I. It will operate at a luminosity up to 2×1034
cm−2s−1, ten times that of the Upgrade I detector. New detector components will improve the intrinsic performance of the experiment in certain key areas. An Expression Of Interest proposing Upgrade II was submitted in February 2017. The physics case for the Upgrade II is presented here in more depth. CP-violating phases will be measured with precisions unattainable at any other envisaged facility. The experiment will probe b → sl+l−and b → dl+l− transitions in both muon and electron decays in modes not accessible at Upgrade I. Minimal flavour violation will be tested with a precision measurement of the ratio of B(B0 → μ+μ−)/B(Bs → μ+μ−). Probing charm CP violation at the 10−5 level may result in its long sought discovery. Major advances in hadron spectroscopy will be possible, which will be powerful probes of low energy QCD. Upgrade II potentially will have the highest sensitivity of all the LHC experiments on the Higgs to charm-quark couplings. Generically, the new physics mass scale probed, for fixed couplings, will almost double compared with the pre-HL-LHC era; this extended reach for flavour physics is similar to that which would be achieved by the HE-LHC proposal for the energy frontier
- …